Abstract: Provided is a polydixylitol polymer gene transporter (VBXYP-P) containing vitamin B6 and a cancer stem cell-targeting peptide (TR-7) and a method for preparing the same. In addition, provided is a nucleic acid delivery complex in which a therapeutic nucleic acid is conjugated to the gene transporter, and a pharmaceutical composition for gene therapy containing the complex as an active ingredient. In addition, provided is the gene transporter, a gene delivery complex, and gene therapy using the same. It was observed that VBXYP-P of the present disclosure had a remarkably higher nucleic acid delivery rate to cancer stem cells than the pre-existing nucleic acid transporter, and when VBXYP-P was conjugated with DNA, the complex was almost free of cytotoxicity and permeated a blood brain barrier to exhibit remarkably high transformation efficiency for cancer stem cells inside a brain tumor.

Abstract: The present invention relates to polydixylitol polymer based gene transporter (PdXYP) and a preparation method thereof. Further, the present invention relates to a nucleic acid delivery complex where the nucleic acids for treatment are conjugated to the gene transporter and a pharmaceutical composition for gene therapy including the complex as an active ingredient. In addition, the present invention relates to the gene transporter, gene delivery complex, and gene therapy using the gene transporter and gene delivery complex. It was confirmed that the PdXYP of the present invention has a considerably higher nucleic acid delivery rate than existing gene transporters, has almost no cytotoxicity in the conjugate when conjugated with DNA, also has very high in vivo transfection efficiency, and above all, especially has considerably high transfection efficiency for brain tissues, which has involved difficulty in gene therapy due to the blood brain barrier for a while.

Abstract: The present invention relates to polydixylitol polymer based gene transporter (PdXYP) and a preparation method thereof. Further, the present invention relates to a nucleic acid delivery complex where the nucleic acids for treatment are conjugated to the gene transporter and a pharmaceutical composition for gene therapy including the complex as an active ingredient. In addition, the present invention relates to the gene transporter, gene delivery complex, and gene therapy using the gene transporter and gene delivery complex. It was confirmed that the PdXYP of the present invention has a considerably higher nucleic acid delivery rate than existing gene transporters, has almost no cytotoxicity in the conjugate when conjugated with DNA, also has very high in vivo transfection efficiency, and above all, especially has considerably high transfection efficiency for brain tissues, which has involved difficulty in gene therapy due to the blood brain barrier for a while.